{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:01:13Z","timestamp":1770897673950,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"national scientific project \u201cThe role of angiogenesis and other microenvironmental factors in the progression and prognosis of plasma cell dyscrasias\u201d","award":["18-104"],"award-info":[{"award-number":["18-104"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: This pilot study examines the expression of MDM2 and NF-\u03baB proteins in CD138-positive plasma cells in patients with multiple myeloma treated with bortezomib-based therapy, exploring their possible interplay and correlations with clinical and selected prognostic factors. Materials and Methods: We analyzed MDM2 and NF-\u03baB protein expression via double immunohistochemical staining of bone marrow trephine biopsies obtained at diagnosis and after bortezomib-based therapy. Statistical analyses were performed to assess the significance of changes in protein expression before and after therapy and their association with clinical and prognostic parameters. Results: Key findings revealed a positive correlation between MDM2 and NF-\u03baB, as well as a significant decrease in their expression following therapy. Decreased NF-\u03baB expression seems to be an independent prognostic factor for improved renal function. Conclusions: The results demonstrated for the first time the in vivo protein expression of MDM2 in the bone marrow of patients with multiple myeloma, as well as the possible effect of bortezomib on the expression of this protein in the microenvironment of multiple myeloma.<\/jats:p>","DOI":"10.3390\/medicina61111948","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:48:28Z","timestamp":1761878908000},"page":"1948","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Association and Significance of MDM2 and NF-\u03baB Protein Expression in Multiple Myeloma"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-0350","authenticated-orcid":false,"given":"Marija","family":"Stani\u0107 Dami\u0107","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Clinical Hospital Center Rijeka, Kre\u0161imirova 42, 51000 Rijeka, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8522-9693","authenticated-orcid":false,"given":"Aron","family":"Grube\u0161i\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Clinical Hospital Center Rijeka, Kre\u0161imirova 42, 51000 Rijeka, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinaida","family":"Peri\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Clinical Hospital Center Rijeka, Kre\u0161imirova 42, 51000 Rijeka, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nives","family":"Jonji\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"Department of Pathology and Cytology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-1497","authenticated-orcid":false,"given":"Irena","family":"Seili-Bekafigo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"Department of Pathology and Cytology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4758-1717","authenticated-orcid":false,"given":"Goran","family":"Hauser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Clinical Hospital Center Rijeka, Kre\u0161imirova 42, 51000 Rijeka, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Jaja\u0161","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Clinical Hospital Center Rijeka, Kre\u0161imirova 42, 51000 Rijeka, Croatia"},{"name":"Faculty of Health Studies, University of Rijeka, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2117-9030","authenticated-orcid":false,"given":"Toni","family":"Valkovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Health Studies, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"Specialty Hospital Medico, 51000 Rijeka, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13045-017-0538-4","article-title":"Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis","volume":"10","author":"Abdi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41419-022-04511-7","article-title":"HERC3 regulates epithelial-mesenchymal transition by directly ubiquitination degradation EIF5A2 and inhibits metastasis of colorectal cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/B978-0-12-380916-2.00003-6","article-title":"MDM2 and MDMX in Cancer and Development","volume":"94","author":"Marine","year":"2011","journal-title":"Curr. Top. Dev. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1054\/drup.2000.0160","article-title":"Disrupting the p53-mdm2 interaction as a potential therapeutic modality","volume":"3","author":"Moll","year":"2000","journal-title":"Drug Resist. Updates"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yamaguchi, H., Hsu, J.L., and Hung, M. (2012). Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer. Front. Oncol., 2.","DOI":"10.3389\/fonc.2012.00015"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bose, I., and Ghosh, B. (2007). The p53-MDM2 network: From oscillations to apoptosis. arXiv.","DOI":"10.1007\/s12038-007-0103-3"},{"key":"ref_7","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","article-title":"The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors","volume":"19","author":"Hou","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12935-024-03356-8","article-title":"MDM2, current research status and prospects of tumor treatment","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1101\/gad.11.15.1974","article-title":"Repression of p53-mediated transcription by MDM2, a dual mechanism","volume":"11","author":"Thut","year":"1997","journal-title":"Genes. Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1593\/neo.121534","article-title":"p53-Independent Roles of MDM2 in NF-\u03baB Signaling: Implications for Cancer Therapy, Wound Healing, and Autoimmune Diseases","volume":"14","author":"Mulay","year":"2012","journal-title":"Neoplasia"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Muthumani, P., Karthikeyan, A., Dhandayuthapani, S., Venkatesan, T., and Rathinavelu, A. (2014). Pro-angiogenic effects of MDM2 through HIF-1\u03b1 and NF-\u03baB mediated mechanisms in LNCaP prostate cancer cells. Mol. Biol. Rep., 41.","DOI":"10.1007\/s11033-014-3430-0"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Moyer, S.M., Larsson, C.A., and Lozano, G. (2017). Mdm proteins: Critical regulators of embryogenesis and homoeostasis. J. Mol. Cell Biol., 9.","DOI":"10.1093\/jmcb\/mjx004"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Faruq, O., Zhao, D., Shrestha, M., Vecchione, A., Zacksenhaus, E., and Chang, H. (2022). Targeting an MDM2\/MYC Axis to Overcome Drug Resistance in Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14061592"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Roy, P., Sarkar, U.A., and Basak, S. (2018). The NF-\u03baB Activating Pathways in Multiple Myeloma. Biomedicines, 6.","DOI":"10.3390\/biomedicines6020059"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1158\/1078-0432.CCR-24-0256","article-title":"MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance","volume":"30","author":"Davis","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-\u03baB in inflammation and cancer","volume":"22","author":"Mao","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wong, A.H., Shin, E.M., Tergaonkar, V., and Chng, W.J. (2020). Targeting NF-\u03baB Signaling for Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12082203"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20394","DOI":"10.18632\/oncotarget.14610","article-title":"Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Labbozzetta, M., Notarbartolo, M., and Poma, P. (2020). Can NF-\u03baB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093070"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/JIR.S140188","article-title":"Mechanisms of NF-\u03baB p65 and strategies for therapeutic manipulation","volume":"11","author":"Giridharan","year":"2018","journal-title":"J. Inflamm. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37377","DOI":"10.18632\/oncotarget.16343","article-title":"NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway","volume":"8","author":"Jana","year":"2017","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1021\/jm401800k","article-title":"Double-edged swords as cancer therapeutics: Novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-\u03baB pathway","volume":"57","author":"Zhuang","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","article-title":"Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells","volume":"66","author":"Roccaro","year":"2006","journal-title":"Cancer Res."},{"key":"ref_27","first-page":"6535","article-title":"Anti-Angiogenic Effect of Bortezomib Treatment in Multiple Myeloma is Associated with Lower NF-KB and OPN Expression","volume":"37","author":"Grubesic","year":"2023","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-021-00492-6","article-title":"Real-world renal function among patients with multiple myeloma in the United States","volume":"11","author":"Singh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1080\/10428194.2020.1867725","article-title":"Renal insufficiency in multiple myeloma: A systematic review and meta-analysis of all randomized trials from 2005\u20132019","volume":"62","author":"Mohyuddin","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1046\/j.1523-1755.2001.00941.x","article-title":"Tubular NF-\u03baB and AP-1 activation in human proteinuric renal disease","volume":"60","author":"Mezzano","year":"2001","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000049056","article-title":"Antagonism of Nuclear Factor Kappa B","volume":"90","author":"Wardle","year":"2002","journal-title":"Nephron J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/1744666X.2019.1561283","article-title":"New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions","volume":"15","author":"Schiano","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1948\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:41:52Z","timestamp":1761882112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111948"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111948","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}